Mantle Cell Lymphoma News and Research

RSS
New TAU study offers tangible hope of curing Mantle Cell Lymphoma

New TAU study offers tangible hope of curing Mantle Cell Lymphoma

New oral breast cancer drug has potential to combat other types of cancer

New oral breast cancer drug has potential to combat other types of cancer

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

Ibrutinib ‘new standard’ for relapsed, refractory mantle cell lymphoma

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

NeoGenomics introduces NeoLAB Solid Tumor Monitor, NeoLAB BTK Inhibitor Acquired Resistance test

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Ibrutinib more effective than traditional chemotherapy in older untreated patients with CLL

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Potential for chemotherapy-free standard of care in advanced mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Drug combination produces long-term responses in patients with mantle cell lymphoma

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Oxis Biotech executes worldwide license agreement to develop, commercialize novel cancer therapy

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

Altering protein recycling complexes in human cells may help overcome chemotherapy resistance

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

IMBRUVICA (ibrutinib) approved in Europe for treatment of Waldenstrom's macroglobulinemia

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

Ibrutinib (IMBRUVICA) improves survival in treatment-naïve patients with chronic lymphocytic leukemia

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

MorphoSys announces updated clinical data on its proprietary drug candidate MOR208

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics's Phase III RESONATE™ trial shows adherence to 420mg dose of IMBRUVICA improves outcomes in CLL patients

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Pharmacyclics’ Ibrutinib Phase Ib/II data show ibrutinib may be safe and effective in patients with cGVHD

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes  in CLL/SLL patients

Phase III HELIOS trial results show ibrutinib combination therapy improves outcomes in CLL/SLL patients

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Pharmacyclics initiates ibrutinib-MEDI4736 combination multi-center study for R/R DLBCL or FL

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Ibrutinib and chemotherapy reduce risk of death in patients with CLL or SLL

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Ibrutinib (IMBRUVICA) may be effective for pancreatic ductal adenocarcinoma

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting

New pre-clinical, clinical data for IMBRUVICA to be highlighted at AACR Annual Meeting